265 related articles for article (PubMed ID: 18533800)
1. Immunotherapy for renal cell cancer in the era of targeted therapy.
Coppin C
Expert Rev Anticancer Ther; 2008 Jun; 8(6):907-19. PubMed ID: 18533800
[TBL] [Abstract][Full Text] [Related]
2. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens.
Miyake H; Sakai I; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
Int J Urol; 2009 May; 16(5):465-71. PubMed ID: 19467119
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
4. "Late" regressions of metastases from renal cancer after a period of disease progression continuing the same intermittent low dose immunotherapy regimen.
Giacosa R; Santi R; Vaglio A; Pavone L; Ferrozzi F; Passalacqua R; Buzio C
Acta Biomed; 2004 Aug; 75(2):126-30. PubMed ID: 15481703
[TBL] [Abstract][Full Text] [Related]
5. Advances in immune-based therapies of renal cell carcinoma.
Lam JS; Belldegrun AS; Figlin RA
Expert Rev Anticancer Ther; 2004 Dec; 4(6):1081-96. PubMed ID: 15606335
[TBL] [Abstract][Full Text] [Related]
6. Multidisciplinary treatment of brain metastases derived from clear cell renal cancer incorporating stereotactic radiosurgery.
Samlowski WE; Majer M; Boucher KM; Shrieve AF; Dechet C; Jensen RL; Shrieve DC
Cancer; 2008 Nov; 113(9):2539-48. PubMed ID: 18780316
[TBL] [Abstract][Full Text] [Related]
7. Cytokine and vaccine therapy of kidney cancer.
Doehn C; Kausch I; Melz S; Behm A; Jocham D
Expert Rev Anticancer Ther; 2004 Dec; 4(6):1097-111. PubMed ID: 15606336
[TBL] [Abstract][Full Text] [Related]
8. The role of cytoreductive nephrectomy in the era of molecular targeted therapy.
Polcari AJ; Gorbonos A; Milner JE; Flanigan RC
Int J Urol; 2009 Mar; 16(3):227-33. PubMed ID: 19207114
[TBL] [Abstract][Full Text] [Related]
9. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.
Parton M; Gore M; Eisen T
J Clin Oncol; 2006 Dec; 24(35):5584-92. PubMed ID: 17158544
[TBL] [Abstract][Full Text] [Related]
10. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies.
Belldegrun AS; Klatte T; Shuch B; LaRochelle JC; Miller DC; Said JW; Riggs SB; Zomorodian N; Kabbinavar FF; Dekernion JB; Pantuck AJ
Cancer; 2008 Nov; 113(9):2457-63. PubMed ID: 18823034
[TBL] [Abstract][Full Text] [Related]
11. Chronically administered immunotherapy with low-dose IL-2 and IFN-alpha in metastatic renal cell carcinoma: a feasible option for patients with a good prognostic profile.
Vaglio A; Alberici F; Maggiore U; Buti S; Potenzoni D; Passalacqua R; Buzio C
Oncology; 2009; 76(1):69-76. PubMed ID: 19047813
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapy for renal cell carcinoma: a new therapeutic paradigm.
Shaheen PE; Bukowski RM
Cancer Invest; 2006 Oct; 24(6):640-56. PubMed ID: 16982470
[TBL] [Abstract][Full Text] [Related]
13. Cytokine therapy for metastatic renal cell carcinoma.
Bukowski RM
Semin Urol Oncol; 2001 May; 19(2):148-54. PubMed ID: 11354535
[TBL] [Abstract][Full Text] [Related]
14. [Cytokine therapy for metastatic renal cell carcinoma].
Eto M; Naito S
Gan To Kagaku Ryoho; 2002 Oct; 29(10):1738-44. PubMed ID: 12402423
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma.
Donskov F
Dan Med Bull; 2007 Nov; 54(4):249-65. PubMed ID: 18208677
[TBL] [Abstract][Full Text] [Related]
16. Current status of cytoreductive nephrectomy in metastatic renal cell carcinoma.
Harshman LC; Srinivas S
Expert Rev Anticancer Ther; 2007 Dec; 7(12):1749-61. PubMed ID: 18062749
[TBL] [Abstract][Full Text] [Related]
17. Cytoreductive nephrectomy for metastatic renal cell carcinoma: is it still imperative in the era of targeted therapy?
Pantuck AJ; Belldegrun AS; Figlin RA
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):693s-696s. PubMed ID: 17255295
[TBL] [Abstract][Full Text] [Related]
18. Cancer immunotherapy using tumor-infiltrating lymphocytes.
Figlin RA
Semin Hematol; 1992 Apr; 29(2 Suppl 1):33-5. PubMed ID: 1535456
[No Abstract] [Full Text] [Related]
19. Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy.
Kwan KG; Kapoor A
Curr Opin Support Palliat Care; 2009 Sep; 3(3):157-65. PubMed ID: 19528804
[TBL] [Abstract][Full Text] [Related]
20. Treatment of metastatic renal cell carcinoma.
Reeves DJ; Liu CY
Cancer Chemother Pharmacol; 2009 Jun; 64(1):11-25. PubMed ID: 19343348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]